Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1
human evidence is still emerging.) Musculoskeletal injury or post-surgical recovery Chronic tendonitis, ligament sprains, or joint pain Athletes or active individuals with overuse injuries Patients with GI inflammation or ulcerative symptoms Individuals seeking regenerative or anti-inflammatory support Generally well-tolerated in available data, but may include: Mild redness or irritation at injection site Transient headache, nausea, or dizziness (rare) Potential for allergic reaction (rare) Not FDA-approved
Weight loss is part of the picture, not the whole picture
04.25.25 Semaglutide user developed NAION, filed lawsuit A man who used semaglutide to manage diabetes alleges that he developed NAION four months after he began taking the drug
Much of your body heat can escape through your head, so wearing a hat can make a significant difference
Heterogeneity was 25.77% with no evidence of publication bias on visible inspection of the funnel plot (Supplemental Fig
